Somatostatin, the endogenous inhibitor of growth hormone release, rises after meals (particularly high-carbohydrate or high-fat meals) and during periods of elevated blood glucose or free fatty acids
Applications under investigation include wound healing, sarcopenia, metabolic regulation, and age-related endocrine decline
Polonikov AV, Ivanov VP, Solodilova MA, Khoroshaya IV, Kozhuhov MA, Ivakin VE, Katargina LN, Kolesnikova OE
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
With retatrutide and other multi-agonists on the horizon, we may soon see drugs that approach the effectiveness of bariatric surgery without the invasiveness